Recursion and Exscientia Shareholders Approve Merger, Paving Way for AI-Driven Drug Discovery Powerhouse

Shareholders Approve Merger of AI Drug Discovery Giants

In a significant move that could reshape the landscape of AI-driven drug discovery, shareholders of Recursion (NASDAQ: RXRX) and Exscientia (NASDAQ: EXAI) have overwhelmingly approved the proposed merger between the two companies. The transaction is expected to close on November 20, 2024, subject to customary closing conditions 1

1

2

2

.

Strategic Rationale and Leadership

Chris Gibson, Ph.D., Co-Founder and CEO of Recursion, who will lead the combined entity, expressed enthusiasm about the merger's potential: "The overwhelming support from both Recursion and Exscientia shareholders further validates our strong rationale for this business combination" 1

1

. The merger aims to synergize Recursion's biological and chemical exploration capabilities with Exscientia's molecular design and automated chemistry synthesis expertise 2

2

.

Technological Synergies

The combination promises to create a powerhouse in the TechBio sector, leveraging advanced technologies from both companies:

1. Recursion's Operating System (OS): A platform that expands one of the world's largest proprietary datasets in biology, chemistry, and patient-centric information 1

   1

   .
2. Exscientia's AI-driven approach: Pioneering the use of AI in drug discovery, with a focus on precision design and integrated experimentation 2

   2

   .

Scale and Computational Power

The merged entity will command impressive resources:

• Experimental scale: Capability to conduct millions of wet lab experiments weekly 1

  1

  .
• Computational power: Operation of one of the world's most powerful supercomputers 2

  2

  .

Market Impact and Future Outlook

This merger represents a significant consolidation in the AI-driven drug discovery space. The combined company aims to:

1. Accelerate the discovery of more effective medicines for patients 2

   2

   .
2. Change the underlying economics of drug discovery 1

   1

   .
3. Rapidly advance scientific ideas into viable treatments 2

   2

   .

Investor and Public Communication

Recursion plans to host an update call on November 20, 2024, at 7:30 a.m. ET, which will be broadcast live on various social media platforms 1

1

. The companies will also file detailed voting results with the U.S. Securities and Exchange Commission 2

2

.

Cautionary Note

While the outlook is optimistic, both companies have issued forward-looking statements, acknowledging the inherent uncertainties and risks in such a significant business combination 1

1

2

2

.

This merger marks a pivotal moment in the intersection of artificial intelligence and drug discovery, potentially setting new standards for efficiency and innovation in pharmaceutical research and development.